1417554-25-6

Basic information

• Product Name: C₆H₅FN₂O₃
• CAS NO: 1417554-25-6
• Molecular Weight: 172.116
• Mol File: 1417554-25-6.mol

Chemical Properties

• CAS DataBase Reference: C₆H₅FN₂O₃(CAS DataBase Reference)
• NIST Chemistry Reference: C₆H₅FN₂O₃(1417554-25-6)
• EPA Substance Registry System: C₆H₅FN₂O₃(1417554-25-6)

Safety Data

• Hazardous Substances Data: 1417554-25-6(Hazardous Substances Data)

Usage

Uses

Used in Oncology:
5-Fluorouracil is used as an anticancer agent for the treatment of breast and gastrointestinal cancers. It works by interfering with the growth of cancer cells, disrupting the process of DNA and RNA synthesis, and ultimately leading to the destruction of cancer cells.
Used in Combination Therapy:
5-Fluorouracil is often used in combination with other cancer treatments to enhance the therapeutic effects and improve patient outcomes. Its synergistic action with other chemotherapy drugs can increase the effectiveness of cancer treatment.
Used in Topical Treatments:
In addition to its systemic administration, 5-Fluorouracil can also be applied topically as a cream for the treatment of certain skin conditions and superficial cancers. The topical application allows for targeted treatment with reduced systemic side effects.
Used in Drug Development:
5-Fluorouracil serves as a basis for the development of new anticancer drugs and drug delivery systems. Researchers are exploring novel formulations and combinations to improve the efficacy and safety of 5-Fluorouracil-based cancer treatments.

Upstream product

• 399-88-2 3-fluoro-4-methylpyridine 
• 33252-59-4 3-fluoro-4-methylpyridine-N-oxide 
• 1417556-12-7 C₈H₈FNO₂ 
• 1417529-73-7 C₆H₆FNO 

Downstream Products

• 1417554-26-7 C₆H₄BrFN₂O₃ 
• 1417554-27-8 C₁₀H₁₀BrFN₂O₅ 

Relevant articles and documents

Structure activity relationship of pyridoxazinone substituted RHS analogs of oxabicyclooctane-linked 1,5-naphthyridinyl novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents (Part-6)

Abstract Oxabicyclooctane linked 1,5-naphthyridinyl-pyridoxazinones are novel broad-spectrum bacterial topoisomerase inhibitors (NBTIs) targeting bacterial DNA gyrase and topoisomerase IV at a site different than quinolones. Due to lack of cross-resistance to known antibiotics they present excellent opportunity to combat drug-resistant bacteria. A structure activity relationship of the pyridoxazinone moiety is described in this Letter. Chemical synthesis and activities of NBTIs with substitutions at C-3, C-4 and C-7 of the pyridoxazinone moiety with halogens, alkyl groups and methoxy group has been described. In addition, substitutions of the linker NH proton and its transformation into amide analogs of AM-8085 and AM-8191 have been reported. Fluoro, chloro, and methyl groups at C-3 of the pyridoxazinone moiety retained the potency and spectrum. In addition, a C-3 fluoro analog showed 4-fold better oral efficacy (ED50 3.9 mg/kg) as compared to the parent AM-8085 in a murine bacteremia model of infection of Staphylococcus aureus. Even modest polarity (e.g., methoxy) is not tolerated at C-3 of the pyridoxazinone unit. The basicity and NH group of the linker is important for the activity when CH2 is at the linker position-8. However, amides (with linker position-8 ketone) with a position-7 NH or N-methyl group retained potency and spectrum suggesting that neither basicity nor hydrogen-donor properties of the linker amide NH is essential for the activity. This would suggest likely an altered binding mode of the linker position-7,8 amide containing compounds. The amides showed highly improved hERG (functional IC50 >30 μM) profile.